Adva-27a is a small molecule that inhibits topoisomerase II.
Sunshine Biopharma and The Research Foundation of the State University of New York (SUNY) will work together to develop the former’s lead compound, Adva-27a, for breast cancer and prostate cancer. They will work to take the drug through various stages of preclinical development as well as Phase I trials.
The Research Foundation of SUNY is acting for and on behalf of Binghamton University. The agreement spans three years and shall be renewed automatically for additional one-year periods until the project is completed.
Adva-27a is a small molecule that inhibits topoisomerase II. This enzyme is found in abundance in multidrug resistant breast cancer as well as in other types of aggressive cancer, according to Sunshine Biopharma and The Research Foundation of SUNY.
“Data published in our issued and pending patent applications have shown that Adva-27a is three times more effective in arresting cancer cell growth than its current market competitor,” according to Steve Slilaty, Sunshine’s president and CEO. “We anticipate completion by the first half of 2012, and if things go as we expect we anticipate Adva-27a to be available for compassionate use by the end of the trial.”
